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Abstract 
Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive 
Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune 
response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in 
other malignancies induces specific antibodies. Antibodies against ALK were detected in sera of 
one of 50 analysed ALK-expressing neuroblastoma patients, 13 of 21 ALK positive non-small cell 
lung carcinoma (NSCLC) patients, 13 of 22 ALK translocation-positive, but NPM-ALK-negative 
lymphoma patients and one of one ALK-positive rhabdomyosarcoma patient, but not in 20 healthy 
adults. These data suggest that boosting a pre-existent anti-ALK immune response may be more 
feasible for patients with ALK-positive NSCLC, lymphomas and rhabdomyosarcomas than for 
tumours expressing wild-type ALK. 
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Introduction 
The expression of the anaplastic lymphoma 
kinase (ALK) is silenced after birth with exception of a 
few scattered neurons in the central nervous system1. 
Almost 90% of Anaplastic Large Cell Lymphoma 
(ALCL) in children and adolescents carry a reciprocal 
translocation t(2;5)(p23;q35) fusing the Anaplastic 
Lymphoma Kinase (ALK) gene to Nucleophosmin 1 
(NPM1) 2-4. The resulting NPM-ALK fusion protein is 
an almost ideal oncoantigen due to its limited 
distribution in normal tissues and key roles in 
oncogenic processes1. An adaptive immune response 
to the resulting oncogenic fusion protein has been 
described in patients with NPM-ALK-positive 
ALCL5-8. Almost all the patients generated 
autoantibodies specific for the oncoantigen, whereas 
antibodies could not be detected in healthy adults or 
children or adults with tumours not expressing 
ALK6,8,9. The magnitude of the antibody response 
inversely correlates with the risk of relapse 8,10. Hence, 
antibody titres might serve as a surrogate for the 
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existence and strength of an adaptive B- and/or T-cell 
response against the aberrant expression of the 
NPM-ALK protein in ALCL, thereby linking the 
immune response against NPM-ALK with the 
ultimate control of NPM-ALK-positive ALCL. As 
oncogenic rearrangements of ALK or full-length ALK 
expression have now been described in other cancers, 
ALK might, serve as an embryonal tumour-associated 
antigen in all ALK-positive malignancies. Indeed, 
ALK vaccination has been shown to be effective in 
preventing disease relapse in a murine tumour model 
of ALCL and non-small cell lung cancer 7,11. 
The existence of an anti-ALK autoantibody 
response in other cancers associated with aberrant 
ALK expression might also implicate the use of 
ALK-directed immunotherapeutic strategies for these 
diseases. For example, about 10% of childhood 
ALK-positive ALCL and the majority of ALK-positive 
Diffuse Large B Cell Lymphomas (DLBCL) express 
ALK-fusion proteins with variant fusion partners 
(X-ALK) besides NPM12,3,12. As the contribution of the 
NPM1 portion of the fusion protein to the induction of 
the immune response is not known, it remains to be 
investigated whether X-ALK fusion proteins likewise 
initiate an immune response.  
Aberrant ALK expression also characterises 
other malignancies. ALK rearrangements occurs in 
3-7% of Non-Small Cell Lung Cancer (NSCLC) 
patients, where an intrachromosomal inversion 
involving the ALK gene locus (inv(2)(p21p23)) and the 
echinoderm microtubule associated protein 4 (EML4) gene 
represents the most common rearrangement 
detected13. ALK positive NSCLC is associated with a 
younger age at diagnosis, a non-smoking history and 
the absence of EGFR mutations14,15. Cellular 
expression of EML4-ALK protein is lower than that 
usually observed in ALK-expressing ALCL rendering 
it difficult to detect by immunohistochemistry (IHC) 
with the ALK1 monoclonal antibody15. 
Overexpression of full length ALK by amplification 
has been described in 80% of alveolar 
rhabdomyosarcomas (RMS) and 20% of embryonal 
RMS. ALK expression is driven by amplification of 
the ALK gene and by increased transcription induced 
by the tumour-specific PAX3-FOXO1 transcription 
factor binding to the third intron of the gene16,17. The 
majority of neuroblastomas, the most common 
extracranial solid tumour in children, express full 
length ALK18,19. The strength of ALK-expression 
differs and is influenced by ALK-amplifications or 
modified by ALK-mutations20.  
In order to investigate whether ALK-expression 
in human tumours generally induces an immune 
response, we analysed the presence of circulating 
ALK-specific antibodies in patients with 
ALK-positive, NPM-ALK negative ALCL, DLBCL, 
NSCLC, neuroblastoma and RMS as well as further 20 
healthy volunteers. 
Patients and Methods 
Study population 
Lymphoma cases were selected from patients 
registered on the ethically approved trials 
NHL-BFM95 or ALCL99 in Germany between 1995 
and 2010 with a diagnosis of ALK-positive ALCL or 
ALK-positive DLBCL by national reference histology. 
The patients/parents had given their informed 
consent to use the material. Selection of cases was 
based on the presence of ALK-staining restricted to 
the cytoplasm, the molecularly confirmed absence of 
NPM-ALK fusion and the availability of serum or 
plasma samples taken at diagnosis. The DLBCL cases 
were shown to express Clathrin (CLTC)-ALK by 
Clathrin-ALK specific RT-PCR2. Comparison of the 
immunohistochemical ALK staining pattern with 
molecular analyses revealed complete concordance 
with our previous study2; NPM-ALK positive ALCL 
expressed ALK in the nucleus as well as the 
cytoplasm while variant ALK fusion proteins lacked 
nuclear ALK-staining.  
Neuroblastoma patients were selected from a 
German cohort enrolled onto and treated according to 
the ethically approved NB97 and NB 2004 trials with 
informed consent. Patients with ALK-expressing 
tumours detected by real-time PCR and available 
serum samples during the first four weeks after initial 
tumour biopsy were included in this study. Mutations 
were analysed by sequencing. 
NSCLC patients (n=21; 7 female, 14 male; age 
range 33-83, median age 59; 14 never smokers) 
were treated at the Colorado Cancer Center. All 
NSCLC patients had stage IV disease at the time of 
blood sampling and were proven ALK-rearrangement 
positive by FISH as previously described21. Two 
patients were on no treatment at the time of sampling, 
all others were receiving treatment with either a 
licensed or experimental ALK inhibitor (Crizotinib, 
n=12; LDK378, n=4; AP26113, n=2) or pemetrexed 
(n=1). 
The patient with ALK-positive alveolar 
rhabdomyosarcoma stage IV showed ALK-staining 
by IHC and was included after informed consent for 
measuring ALK antibodies had been secured. 
20 healthy adults were included as control group 
in a study about the characterisation of the cellular 
and humoral ALK-immune response approved by the 
ethical committee of the corresponding authors 
(number: 193/11) after written informed consent. 
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Detection of the antibody response against 
ALK 
Cytocentrifuge preparations of COS-1 cells 
(DSMZ, Braunschweig, Germany) transiently 
transfected with pcDNA3expression plasmids 
harbouring the entire coding sequences of NPM-ALK, 
Tropomyosin 3 (TPM3)-ALK, EML4-ALK, full length 
ALK or pcDNA3 vector only were prepared and 
incubated with patient’s serum diluted 1/50 and 
1/100. Patients with a positive staining result were 
further analysed using serial 3 fold dilution of the 
serum from 1/250 to 1/60750 as previously 
described8. Antigen-antibody complexes were 
visualised by indirect immunoperoxidase staining 
using HRP-rabbit anti-human IgG antibody and 
diaminobezidine-tetrahydrochloride. The cut-off for a 
positive result was taken as the highest dilution 
before the staining of the ALK transfectants was no 
longer visible by two independent observers5. Cos-1 
cells transfected with pcDNA3 vector only were used 
to control for background as well as false positive 
staining. 
Results and Discussion 
We studied 94 patients with ALK-positive, 
NPM-ALK negative malignancies and 20 healthy 
control persons for the presence of anti-ALK titres as a 
surrogate for the existence and strength of the 
immune response against ALK. The range of 
malignancies examined included Lymphoma (ALCL 
and DLBCL), neuroblastoma, NSCLC and one case of 
rhabdomyosarcoma.  
ALK-positive lymphoma was diagnosed in 22 
children/adolescents at a median age of 12.4 years 
(range 2.3-18.2 years). All tumours had ALK 
translocations but were NPM-ALK fusion negative. Of 
the 20 patients diagnosed with X-ALK positive ALCL 
12 (60%) mounted a specific antibody response 
against ALK with titres ranging from 1/250 to 
1/60750 (median 1/750; Table 1). This is a lower 
incidence than previously reported for patients with 
NPM-ALK-positive ALCL of whom 90% produce 
ALK-antibodies although it must be considered that 
the numbers of patients assessed in this study is 
considerably lower 8, 9. ALK-specific antibodies were 
detected in one of the two patients with CLTC-ALK 
positive DLBCL (titre: 1/6750).  
In contrast, only one of the 50 children (median 
age 1.3 years, range 0.1-13.3) with ALK-expressing 
neuroblastoma (including four cases with MYC-N 
amplification and 11 with chromosome 
1p-abnormalities) had a detectable antibody titre, and 
even this response was weak (1/100). This patient had 
stage 4 disease; the tumour didn’t show MYC-N 
amplification or 1p deletion or somatic ALK 
mutations. The characteristics of ALK-expression in 
neuroblastoma differ in many aspects from those of 
lymphoma patients, which may account for the 
missing immune response: Transmembrane 
full-length ALK or variants with point mutations are 
expressed in neuroblastoma and ALK is usually 
expressed at far lower levels in neuroblastoma than 
are detected in ALCL. In addition to the differences in 
ALK-expression in neuroblastoma, the generation of 
ALK antibodies in patients with ALK-positive cancer 
likely also involves other factors. These include the 
levels of expression of the oncoprotein itself but also 
other tumour characteristics and the tumour 
microenvironment. For example, it has been reported 
that neuroblastoma cells can dampen the immune 
response by down-regulating expression of HLA 22, 23 . 
Furthermore, they release soluble inhibitors of the 
immune system, e.g. gangliosides 24. Additionally, 
since neuroblastomas often arise prenatally further 
tolerance mechanisms may be active.  
 
Table 1: Anti-ALK antibody titres in patients with ALK positive 
malignancies other than NPM-ALK-positive ALCL 
 ALCL DLBCL RMS NBL NSCLC 
N 20 2 1  50 21 
ALK aberration      
Translocation/inversion 20 2 - - 21 
Amplification - - 1 - - 
Point mutation - - - 6 - 
No specific aberration - - - 44 - 
Anti-ALK titre       
0 8 1 0 49 8 
≤ 1/750 3 0 1 1 10 
1/2250-1/20250 5 1 0 0 2 
≥ 1/60750 4 0 0 0 1 
Stage*      
1 1 0 0 18 0 
2 5 2 0 8 0 
3 10 0 0 7 0 
4 3 0 1 12 21 
4 S N/A N/A N/A 5 N/A 
Not known 1 - - - - 
outcome      
CCR 15 1 0 32 1 
Relapse/alive 5 0 0 6 11a 
Relapse/DOD 0 1 1 12 6b 
Unknown     3 
* Stage definitions according to disease: Lymphoma: St. Jude staging system; 
Neuroblastoma: INSS. 
ALCL, anaplastic large cell lymphoma; DLBCL, diffuse large B cell lymphoma; 
N/A, not applicable; CCR, continuous complete remission; DOD, death of disease; 
a stable disease; b disease progression 
 
 
In contrast to the patients with ALK-positive 
neuroblastoma, the 19 year old patient with alveolar 
RMS and high expression of full-length ALK clearly 
produced ALK antibodies. Even though only one 
RMS patient was assessed this suggests that 
expression of full length ALK does not preclude the 
immune response and that anti-ALK immunity 
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should be systematically analysed in ALK-positive 
RMS. 
The majority of ALK expressing NSCLC patients 
had progressive disease and 19 of the 21 had 
undergone prior chemotherapy, in some cases 
multiple rounds. Prior therapies and long-standing 
disease might have suppressed the immune response 
or, at least, lowered the antibody titre as has been 
observed in ALCL-patients9. Therefore, the strength 
of the immune response might not reflect the titres at 
initial diagnosis. Despite this limitation, 10 of the 21 
ALK-positive NSCLC patients mounted a weak 
antibody response against ALK (≤1/750) with eight 
having no titre at all, two patients displaying 
moderate titres (>750-<60750) and one patient having 
a high titre (≥1/60750) (Table 1). In addition to the 
influence of prior therapy on the antibody response, 
NSCLC, like neuroblastoma, express lower cellular 
levels of aberrant ALK in comparison to 
lymphomas21. Furthermore, as in neuroblastoma, 
HLA-down-regulation has been described in 
NSCLC25. However, these data do indicate that an 
ALK-specific immune response exists in 
NSCLC-patients. Our results raise the possibility of 
boosting the ALK-directed immune response as a 
therapeutic strategy in patients with ALK-positive 
NSCLC which is of special interest in light of the still 
dismal prognosis even with ALK-inhibitor therapy. 
Furthermore, these data suggest that further studies 
of ALK antibody titre in NSCLC are warranted, in 
particular of patients at first disease presentation.  
The sera of X-ALK-positive ALCL-patients in 
this study reacted against NPM-ALK, TPM3-ALK and 
full-length-ALK transfected COS cells and sera from 
patients with NPM-ALK- positive ALCL stained cells 
expressing theTPM3-ALK fusion protein 
(Supplementary Figure S1). Likewise, sera from 
ALK-positive NSCLC patients stained both 
EML4-ALK and NPM-ALK transfectants (data not 
shown). These data suggest that the auto-antibodies 
target the ALK-portion of the fusion proteins 
indicating that the immune response is directed 
against the embryonal ALK tumour-associated 
antigen rather than an epitope from the 
tumour-specific X-ALK fusion site.  
None of the 20 healthy control persons had 
detectable anti-ALK antibodies in their serum. 
Together with our previous data this equates to more 
than 100 adults without ALK-expressing tumours (50 
healthy at the time of analysis) who do not have a 
detectable humoral immune response against ALK. 
These data suggest that unspecific autoimmune 
reactions against ALK are rare in the absence of 
ALK-expressing tumours. 
In summary, antibody responses against ALK 
fusion proteins are not restricted to 
NPM-ALK-positive ALCL but can be detected in most 
patients with variant ALK-fusion partners in both 
ALCL and DLBCL, as well as in one ALK-positive 
RMS and half of the patients with ALK-positive 
NSCLC in contrast to the vast majority of patients 
with ALK-positive neuroblastoma. Our data suggests 
that inter-individual differences in immune response 
modifiers may not be the sole determinant as to 
whether a patient elicits an immune response against 
ALK. Dependent on the strength and kind of ALK 
expression (full-length versus fusion protein), tumour 
cell type and age at tumour development, different 
immune escape mechanisms may be active. Boosting 
a pre-existent anti-ALK immune response may be 
more feasible for patients with ALK-positive NSCLC, 
lymphomas and rhabdomyosarcomas than for 
tumours expressing wild-type ALK. 
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